Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

549

Participants

Timeline

Start Date

December 18, 2017

Primary Completion Date

February 19, 2024

Study Completion Date

December 31, 2025

Conditions
Recurrent or Metastatic Breast Cancer
Interventions
DRUG

Oral paclitaxel

Oral administration on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent

DRUG

Paclitaxel injection

Premedication, intravenous infusion on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent

Trial Locations (51)

1330

"Medical Center Nadezhda Clinical Ltd.,", Sofia

2800

Szent Borbála Hospital, Tatabánya

4500

Multi-profile Hospital for Active Treatment Uni Hospital Ltd. Medical Oncology Department, Panagyurishte

7100

Tolna County Balassa János Hospital, Szekszárd

8000

Oncology Complex Center - Burgas'' Ltd., Medical Oncology Department, Burgas

10408

National Cancer Center, Goyang-si

11000

Institute for Oncology and Radiology of Serbia, Belgrade

11080

Clinical Hospital Center Bežanijska Kosa, Department of Oncology, Belgrade

13496

Cha University Cha Bundang Medical Center, Seongnam-si

16499

Ajou University Hospital, Suwon

18000

Clinical Center Niš, Clinic for Oncology, Niš

19320

Health Center Kladovo, Oncology Department, Kladovo

21204

Oncology Institute of Vojvodina, Kamenitz

28644

Chungbuk National University Hospital, Cheongju-si

34000

Clinical Center Kragujevac Center of Oncology and Radiotherapy, Kragujevac

35365

Konyang University Hospital, Daejeon

37000

General Hospital Krusevac, Outpatient Clinic for chemotherapy, Kruševac

Unknown

Anhui Cancer Hospital, Hefei

Cancer Hospital Chinese Academy Of Medical Sciences, Beijing

Sun Yat-sen University Cancer Center, Guangzhou

The First Affiliated Hospital Of Hainan Medical College, Haikou

Harbin Medical University Cancer Hospital, Harbin

Tianjin Cancer Hospital, Zhengzhou

Jiangsu Cancer Hospital, Nanjing

Jiangsu Province Hospital, Nanjing

First Affiliated Hospital of Jilin University, Changchun

Liaoning Cancer Hospital, Shenyang

Shangdong Cancer Hospital, Jinan

Linyi Cancer Hospital, Linyi

Fudan University Shanghai Cancer Center, Shanghai

The First Affiliated Hospital of Xi'an Jiaotong university, Xi’an

West China School Of Medicine Sichuan University, Chengdu

Zhejiang Cancer Hospital, Hangzhou

Zhejiang University School Of Medicine Sir Run Run Shaw Hospital, Hangzhou

Henan Cancer Hospital, Zhengzhou

Kosin University Gospel Hospital, Busan

Pusan National University Yangsan Hospital, Busan

Keimyung University Dongsan Medical Center, Daegu

Gang Neung Asan Hospital, Gangneung

Gachon University Gil Medical Center, Incheon

Catholic University of Korea Seoul ST. Mary's Hospital, Seoul

Gangnam Severance Hospital, Seoul

Uijeongbu ST. Mary's Hospital, Uijeongbu-si

220-701

Wonju Severance Christian Hospital, Wŏnju

612-896

Inje University Haeundae Paik Hospital, Busan

02841

Korea University Anam Hospital, Seoul

03080

Seoul National University Hospital, Seoul

03722

Yonsei University Severance Hospital, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

08308

Korea University Guro Hospital, Seoul

All Listed Sponsors
lead

Daehwa Pharmaceutical Co., Ltd.

INDUSTRY

NCT03315364 - Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy | Biotech Hunter | Biotech Hunter